Gupta Durgesh Kumari, Goswami Raksha, Kumawat Deepak, Gupta Anjana, Chandy Steffy Mary
email@example.com , firstname.lastname@example.org
Gupta Durgesh Kumari1, Goswami Raksha2, Kumawat Deepak3, Gupta Anjana3, Chandy Steffy Mary3
1AKS University, Satna (M. P.).
2Oriental College of Pharmacy and Research, Indore (M. P.).
3Acropolis Institute of Pharmaceutical Education and Research, Indore.
Volume - 10,
Issue - 4,
Year - 2020
Chitosanis a characteristic polysaccharide arranged by the N-deacetylation of chitin. Chitosan arebiologically safe, biocompatible biodegradable, non-toxic polysaccharide. Chitosan nanoparticles carry more study in drug delivery system because it shows better stability, low toxicity, simple and mild preparation method and they include the various route of administration like oral, nasal, IV and ocular. Chitosan contain the various functional groups that can be adjust to achieve a specific goals and making it a polymer with a huge range of inherent applications. Nanoparticle are prepared with the chitosan and chitosan derivatives and they hold a positive surface charge and mucoadhesive properties such as that can adhere to mucus membranes and the drug released payload in a sustained release manner. Chitosan has itself many medicinal properties like antimicrobial, antioxidant, and low immunogenicity etc. Chitosan-based nanoparticle have attracted increasing attention for their wide application in non-parenteral drug delivery for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections. Chitosan have low toxicity both in vitro and some in vivo models. In evaluation of nanoparticles various parameters are used such as Drug Content / Drug entrapment, Particle Size, Zeta Potential, Surface Morphology, In-vitro release Study, Kinetic Study, and Stability of nanoparticles. InThis review explores recent research on chitosan based nanoparticle for drug delivery, chitosan properties, and modification, toxicity, preparation, evaluation and application studies.
Cite this article:
Gupta Durgesh Kumari, Goswami Raksha, Kumawat Deepak, Gupta Anjana, Chandy Steffy Mary. A Review on Chitosan Nanoparticle as a Drug delivery system. Asian J. Pharm. Res. 2020; 10(4):299-306. doi: 10.5958/2231-5691.2020.00051.9
1. M. AbdulhussienAljebory and Tamadhur M. Alsalman, Chitosan Nanoparticles: Review Article Imperial Journal of Interdisciplinary Research (IJIR) Vol-3, Issue-7, 2017.
2. Bangun H., Tandiono s., Arianto A., Preparation and evaluation of chitosan-tri polyphosphate nanoparticles suspension as an antibacterial agent, Journal of Applied Pharmaceutical Science, 2018: 8(12); 147-156.
3. Tiruwa, R., A review on nanoparticles–preparation and evaluation parameters, Indian Journal Pharmaceutical Biotechnology Research, 2015; 4(2):27-31.
4. Muhamad, I. I., Selvakumaran S., Lazim M. d., Nurul A., Designing Polymeric Nanoparticles for Targeted Drug Delivery System, 2012; 3(4):287-313.
5. Qi, Lifeng, Xu, Zirong., Jiang, Xia., Hu, Caihong., Zou, Xiangfei., Preparation and antibacterial activity of chitosan nanoparticles Carbohydrate Research, 2004; 339(16);2693–2700.
6. Katas H., Chei S., Yasser A., Hamdi N. A., FhataheyaBuang, MohdFauziMhBusra Antibacterial activity of biosynthesized gold nanoparticles using biomolecules from Lignosusrhinocerotis and chitosan, Saudi Pharmaceutical Journal, (2019): 27 :283–292.
7. Hasan, S., A Review on Nanoparticles: Their Synthesis and Types, Research Journal of Recent Sciences 2015; 4(1):1-3.
8. Kumar, N., Patel, A. K., Kumar, N., A Review on chitosan nanoparticles for cancer treatment, Journal of controlled release, 2014; 4(4): 63-35.
9. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and bio distribution of polymeric nanoparticles. Mol. Pharmacology, 2008; 5(4): 505-15.
10. Shah, Jogani, Mishra, Mishra A.K., Bagchi T, Mishra A. Modulation of Gancyclovir intestinal absorption in presence of absorption enhancers. J. Pharm Sci, 2007; 96(27): 10-22.
11. Schipper N G M, Varum K M, Artursson. Chitosan’s as absorption enhancers for poorly absorbable drugsb Influence of molecular weight and degree of Deacetylation on drug transport across human intestinal epithelial cells. Pharm Res., 1996; 13(11): 1686-1692.
12. Kast C.E., Bernkop- Schnurch A. Influence of the molecular mass on the permeation enhancing effect of different poly (acrylates), STP Pharm Sci, 2002; 6(35):1-6.
13. Naresh Kumar, Anil Kumar Patel, NeerajKumari and Amit Kumar, A review on chitosan nanoparticles for cancer treatment International Journal of Nanomaterial and Bio structures 2014; 4(4): 63-65.
14. WareeTiyaboonchai, Chitosan Nanoparticles: A Promising System for Drug Delivery, Naresuan University Journal 2003; 11(3): 112-115.
15. A krishnasailaja, amareshwar, chakravarty, chitosan nanoparticles as a drug delivery system research journal of pharmaceutical, biological and chemical sciences, (2010); 1(475): 50-52.
16. Dwivedi S., Mahor A. and Chanchal D., chitosan nanoparticles: a review World Journal of Pharmacy and Pharmaceutical Sciences, 2016; 5(1): 75-79.
17. Tarek A Ahmed, Bader M. Aljaeid, Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery, Drug Design, Development and Therapy, 2016; 10: 483–507.
18. Agarwal Megha, Agarwal Mukesh Kumar, Srivastava Nalini, Pandey Sarika, Das Ritu, Gaur Priyanka, Preparation of Chitosan Nanoparticles and their In-vitro Characterization, International journal of life science scientific research,2018;4(2):1713-1720.
19. J. J. Wang, Z. W. Zeng, R. Z. Xiao, T. Xie, Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nano med., 2011; 6: 765-74.
20. U. Termsarasab, I. S. Yoon, J. H. Park, H. T. Moon, H. J. Cho, and D. D. Kim, Polyethylene glycol-modified Arachidyl chitosan-based nanoparticles for prolonged blood circulation of doxorubicin. Int. J. Pharm., 2014; 464(1-2):127-34.
21. Sheng Y., Liu C., Yuan Y., Tao X., Yang F., Shan X., Zhou H., and Xu F., Long-circulation polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials, 2009; 30(12): 2340-2348.
22. J. J. Wang, Z. W. Zeng, R. Z. Xiao, T. Xie, G. L. Zhou, X. R. Zhan, and S. L. Wang, Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nano med. 6, 765 (2011).54.
23. H. Koo, K. H. Min, S. C. Lee, J. H. Park, K. Park, S. Y. Jeong, K. Choi, I. C. Kwon, and K. Kim, Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. J. Control Release. 172, 823 (2013).
24. B. Teong, C. Y. Lin, S. J. Chang, G. C. Niu, C. H. Yao, I. F. Chen, and S. M. Kuo, Enhanced anti-cancer activity by curcumin-loaded hydrogel nanoparticle derived aggregates on A549 lung adenocarcinoma cells. J. Mater. Sci. Mater. Med. 26, 1 (2015).
25. Y. Sheng, C. Liu, Y. Yuan, X. Tao, F. Yang, X. Shan, H. Zhou, and F. Xu, Long-circulatin polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 30, 2340 (2009).
26. U. Term sarasab, I. S. Yoon, J. H. Park, H. T. Moon, H. J. Cho, and D. D. Kim, Polyethylene glycol-modified arachidyl chitosan-based nanoparticles for prolonged blood circulation of doxorubicin. Int.J. Pharm. 464, 127 (2014).
27. Y. Patil, T. Sadhukha, L. Ma, and J. Panyam, Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136, 21 (2009).
28. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J. I. Zink, and A. E. Nel, Engineered design of meso porous silica nanoparticles to deliver doxorubicin and P-Glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4, 4539 (2010).
29. W. Lu, J. Wan, Z. She, and X. Jiang, Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticles. J. Control. Release 118, 38 (2007).
30. G. Zhao, J. Wang, X. Peng, Y. Li, X. Yuan, and Y. Ma, Facile Solve thermal synthesis of meso structured FeO/chitosan nanoparticles as delivery vehicles for pH-responsive drug delivery and magnetic resonance imaging contrast agents. Chem. Asian J. 9, 546 (2014).
31. J. Y. Yhee, S. Son, S. H. Kim, K. Park, K. Choi, and I. C. Kwon, Self-assembled glycol chitosan nanoparticles for disease-specific the ranostics. J. Control. Release 193, 202 (2014).